TY - JOUR
T1 - International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients
AU - Charlton, Michael
AU - Levitsky, Josh
AU - Aqel, Bashar
AU - O'Grady, John
AU - Hemibach, Julie
AU - Rinella, Mary
AU - Fung, John
AU - Ghabril, Marwan
AU - Thomason, Ray
AU - Burra, Patrizia
AU - Little, Ester Coelho
AU - Berenguer, Marina
AU - Shaked, Abraham
AU - Trotter, James
AU - Roberts, John
AU - Rodriguez-Davalos, Manuel
AU - Rela, Mohamed
AU - Pomfret, Elizabeth
AU - Heyrend, Caroline
AU - Gallegos-Orozco, Juan
AU - Saliba, Faouzi
N1 - Funding Information:
M.C. received research support and is a consultant for Gilead, Merck, Janssen, Bristol Myers, Novartis, and AbbVie. M.B. received grants from Gilead and is a member of the advisory boards for Gilead, Abbvie, MSD, BMS, partially funded by the Instituto de Salud Carlos III (ISCIII). P.B. is in the advisory board, speaker of Astellas, Gilead, Kedrion, Biotest, and Sandoz, travel in the last 2 years supported by Astellas, Gilead, Kedrion, Biotest, and Sandoz. M.R. is a consultant for Gilead, Enanta, Intercept, Genfit, Chronic Liver Disease Foundation, and Novartis. J.F.
Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Effective immunosupression management is central to achieving optimal outcomes in liver transplant recipients. Current immunosuppression regimens and agents are highly effective in minimizing graft loss due to acute and chronic rejection but can also produce a substantial array of toxicities. The utilization of immunosuppression varies widely, contributing to the wide disparities in posttransplant outcomes reported between transplant centers. The International Liver Transplantation Society (ILTS) convened a consensus conference, comprised of a global panel of expert hepatologists, transplant surgeons, nephrologists, and pharmacologists to review the literature and experience pertaining to immunosuppression management to develop guidelines on key aspects of immunosuppression. The consensus findings and recommendations of the ILTS Consensus guidelines on immunosuppression in liver transplant recipients are presented in this article.
AB - Effective immunosupression management is central to achieving optimal outcomes in liver transplant recipients. Current immunosuppression regimens and agents are highly effective in minimizing graft loss due to acute and chronic rejection but can also produce a substantial array of toxicities. The utilization of immunosuppression varies widely, contributing to the wide disparities in posttransplant outcomes reported between transplant centers. The International Liver Transplantation Society (ILTS) convened a consensus conference, comprised of a global panel of expert hepatologists, transplant surgeons, nephrologists, and pharmacologists to review the literature and experience pertaining to immunosuppression management to develop guidelines on key aspects of immunosuppression. The consensus findings and recommendations of the ILTS Consensus guidelines on immunosuppression in liver transplant recipients are presented in this article.
UR - http://www.scopus.com/inward/record.url?scp=85046537542&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046537542&partnerID=8YFLogxK
U2 - 10.1097/TP.0000000000002147
DO - 10.1097/TP.0000000000002147
M3 - Review article
C2 - 29485508
AN - SCOPUS:85046537542
SN - 0041-1337
VL - 102
SP - 727
EP - 743
JO - Transplantation
JF - Transplantation
IS - 5
ER -